Search

everythinglearnresearchcommunity

for

Search:↓

User has hair loss, finasteride for 5 years not effective. Considers trying dutasteride, minoxidil, or pyrilutamide.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The user is considering dividing 1mg finasteride pills into quarters despite instructions not to. They currently divide 5mg pills into smaller doses and want to switch to 1mg pills.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

A 25-year-old switched from finasteride to dutasteride, experiencing significant hair regrowth and improved hair quality after 6 months, taking it three times a week. The user stopped finasteride entirely, citing dutasteride's longer half-life as more effective.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

Switching from topical finasteride to oral Dutasteride and using Fluridil caused persistent testicular discomfort. The discomfort did not subside after stopping Fluridil, raising concerns about Dutasteride's role.

Dutasteride effectively stops hair loss but can cause side effects like sexual dysfunction, muscle mass changes, and testicle shrinkage. Adjusting the dosage may help manage these side effects, but long-term health effects remain a concern.

The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

A user has been on finasteride for over 1.5 years but is still losing hair, so they're switching to dutasteride and taking both for 3 months before stopping finasteride. They're concerned about potential hair shedding during the switch even when done correctly.

The conversation discusses the effectiveness of different doses of finasteride for hair loss, questioning the need for 1mg daily when 0.5mg every other day has a similar impact on scalp DHT. A humorous reply suggests exaggerated side effects.

The small soft-gel capsule inside Duodart contains dutasteride, and the powder/beads contain tamsulosin. You can open the large capsule and take only the dutasteride soft-gel.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The conversation discusses the role of DHT in male hair loss and the effectiveness of treatments like Finasteride, which reduces DHT, and RU58841, which blocks DHT from binding to scalp receptors. The user debates the trade-offs between maintaining hair and having a healthy endocrine system, suggesting RU58841 might allow for both.

The user experienced hair thickening and regrowth using dutasteride on alternate days, oral minoxidil every third day, and daily hair massages, but is dealing with dandruff and inflammation. They are considering adjusting their minoxidil dosage and have started using ketoconazole shampoo and cupping therapy for additional benefits.

Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

Dutasteride 0.5mg daily led to significant hair regrowth in 3 months, with minimal side effects like slight pelvic pain and increased libido. The user switched from Finasteride to Dutasteride, noticing reduced hair shedding and improved hair condition.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

The effectiveness of Finasteride/Dutasteride for treating hair loss, and a cautionary tale about potential side effects such as gynecomastia.

The user experienced significant hair regrowth in the temple area after using 1mg finasteride daily for over a year, with no side effects. The user did not use minoxidil or microneedling and started experiencing hair loss at age 16.